Skip to main content

Afeyan Noubar's Form 4 filing

Sana Biotechnology, Inc. (SANA) · filed May 26, 2023

Accession no.
0000899243-23-013992
Filed
May 26, 2023, 8:00 PM ET
Trade date
May 24-26, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $3.53M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Afeyan NoubarCIK 000122201210% Owner
Flagship Ventures Fund V, L.P.CIK 000162763910% Owner
Flagship Ventures Fund V General Partner LLCCIK 000172457510% Owner
Flagship V VentureLabs Rx Fund, L.P.CIK 000172493910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 24, 2023Common StockSSaleDisposed−308,290$6.57−$2,023,985.5111,276,909Indirect
May 24, 2023Common StockSSaleDisposed−39,580$6.57−$259,850.621,447,791Indirect
May 25, 2023Common StockSSaleDisposed−102,245$6.35−$649,480.6911,174,664Indirect
May 25, 2023Common StockSSaleDisposed−13,127$6.35−$83,385.331,434,664Indirect
May 26, 2023Common StockSSaleDisposed−72,670$6.23−$452,479.7611,101,994Indirect
May 26, 2023Common StockSSaleDisposed−9,330$6.23−$58,093.251,425,334Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)